Intranasal H102 Peptide-Loaded Liposomes for Brain Delivery to Treat Alzheimer’s Disease

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Pharmaceutical Research

• Publication date

  2015-06-26

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s11095-015-1744-9PMID 26113236
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Use of Autoantigen-Loaded Phosphatidylserine-Liposomes to Arrest Autoimmunity in Type 1 Diabetes

  2015cited by this paper
• The potential use of H102 peptide-loaded dual-functional nanoparticles in the treatment of Alzheimer's disease.

  2014influential reference
• Feasibility of β-Sheet Breaker Peptide-H102 Treatment for Alzheimer's Disease Based on β-Amyloid Hypothesis

  2014influential reference
• Development of a dual nanocarrier system as a potential stratagem against amyloid-induced toxicity

  2014cited by this paper
• Microfluidic Preparation of Liposomes to Determine Particle Size Influence on Cellular Uptake Mechanisms

  2014cited by this paper
• Amphiphilic glycopolymer nanoparticles as vehicles for nasal delivery of peptides and proteins.

  2013cited by this paper
• Pharmacological Characterization of Memoquin, a Multi-Target Compound for the Treatment of Alzheimer's Disease

  2013cited by this paper
• Effects of β-sheet breaker peptides on altered responses of thoracic aorta in rats' Alzheimer's disease model induced by intraamygdaloid Aβ40.

  2013cited by this paper
• The γ-secretase inhibitor 2-[(1R)-1-[(4-chlorophenyl)sulfonyl](2,5-difluorophenyl) amino]ethyl-5-fluorobenzenebutanoic acid (BMS-299897) alleviates Aβ1-42 seeding and short-term memory deficits in the Aβ25-35 mouse model of Alzheimer's disease.

  2013cited by this paper
• Enhancement of nose-to-brain delivery of basic fibroblast growth factor for improving rat memory impairments induced by co-injection of β-amyloid and ibotenic acid into the bilateral hippocampus.

  2012cited by this paper
• Absorption-promoting effects of chitosan in airway and intestinal cell lines: a comparative study.

  2012cited by this paper
• Intraneuronally injected amyloid β inhibits long-term potentiation in rat hippocampal slices.

  2012cited by this paper
• Interactions of AChE with Aβ Aggregates in Alzheimer’s Brain: Therapeutic Relevance of IDN 5706

  2011cited by this paper
• A rational design to create hybrid β-sheet breaker peptides to inhibit aggregation and toxicity of amyloid-β

  2011cited by this paper
• Novel insights for the treatment of Alzheimer's disease.

  2011cited by this paper
• Effect of Tong Luo Jiu Nao on Aβ-degrading enzymes in AD rat brains.

  2011cited by this paper
• Fast and robust extraction of hippocampus from MR images for diagnostics of Alzheimer's disease

  2011cited by this paper
• Nose-to-Brain Transport Pathways of Wheat Germ Agglutinin Conjugated PEG-PLA Nanoparticles

  2011cited by this paper
• Tight junction modulation by chitosan nanoparticles: comparison with chitosan solution.

  2010cited by this paper
• Intranasal delivery to the central nervous system: mechanisms and experimental considerations.

  2010cited by this paper
• Biodegradation, biodistribution and toxicity of chitosan.

  2010cited by this paper
• In situ gel based on gellan gum as new carrier for nasal administration of mometasone furoate.

  2009cited by this paper
• Validation of Abeta1-40 administration into mouse cerebroventricles as an animal model for Alzheimer disease.

  2009cited by this paper
• Delivery of nerve growth factor to brain via intranasal administration and enhancement of brain uptake.

  2009cited by this paper
• Intranasal bFGF-induced progenitor cell proliferation and neuroprotection after transient focal cerebral ischemia.

  2008cited by this paper
• SYMPOSIUM: Clearance of Aβ from the Brain in Alzheimer's Disease: Aβ‐Degrading Enzymes in Alzheimer's Disease

  2008cited by this paper
• Abeta-degrading enzymes in Alzheimer's disease.

  2008cited by this paper
• Forecasting the global burden of Alzheimer's disease

  2007cited by this paper
• Liposomal drug delivery systems: an update review.

  2007cited by this paper
• Nanoparticulate systems for nasal delivery of drugs: a real improvement over simple systems?

  2007cited by this paper
• Intranasal Insulin to Improve Memory Function in Humans

  2007cited by this paper
• A decade of modeling Alzheimer's disease in transgenic mice.

  2006cited by this paper
• Model organisms: Drug discovery in dementia: the role of rodent models

  2006cited by this paper
• Endothelin-converting enzyme-1 is expressed in human cerebral cortex and protects against Alzheimer's disease

  2004cited by this paper
• Beta-sheet breaker peptide prevents Abeta-induced spatial memory impairments with partial reduction of amyloid deposits.

  2004cited by this paper
• Posttranslational modifications of tau--role in human tauopathies and modeling in transgenic animals.

  2004cited by this paper
• Endothelin-converting enzyme-1 is expressed in human cerebral cortex and protects against Alzheimer's disease

  2004cited by this paper
• β-sheet breaker peptide prevents Aβ-induced spatial memory impairments with partial reduction of amyloid deposits

  2004cited by this paper
• Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo

  2002cited by this paper
• Trends and developments in liposome drug delivery systems.

  2001cited by this paper
• Transport of drugs from the nasal cavity to the central nervous system.

  2000cited by this paper
• Inhibition of Alzheimer's amyloidosis by peptides that prevent beta-sheet conformation.

  1996cited by this paper
• [Toxicity of drugs on nasal mucocilia and the method of its evaluation].

  1995cited by this paper
• Estimation of variance for AUC in animal studies.

  1993cited by this paper

• Advances in nanocarrier-based nose-to-brain drug delivery systems for neurological disorders - A comprehensive review

  2026cites this paper
• Intranasal delivery of biotherapeutics utilizing nanocarriers: Advancements in surface engineering, clinical progress and the incorporation of artificial intelligence

  2026cites this paper
• Redesigning valproic acid therapy in pregnancy: intranasal liposomes for targeted maternal treatment

  2026cites this paper
• Next-Generation Drug Delivery for Neurotherapeutics: The Promise of Stimuli-Triggered Nanocarriers

  2025cites this paper
• Brain Delivery Strategies for Biomacromolecular Drugs: Intranasal Administration

  2025cites this paper
• REVOLUTIONIZING ALZHEIMER’S THERAPEUTICS: FROM MICROTECHNOLOGIES TO AI-DRIVEN INNOVATIONS

  2025cites this paper
• Advances in cell-penetrating peptide-based nose-to-brain drug delivery systems.

  2025cites this paper
• NANOTECHNOLOGY-DRIVEN THERAPEUTICS: ENHANCING BRAIN DRUG DELIVERY VIA NASAL PATHWAYS

  2025cites this paper
• Engineering Liposomes for Neurodegenerative Diseases: Targeted Delivery and Regenerative Potential

  2025cites this paper
• Current amyloid inhibitors: therapeutic applications and nanomaterial-based innovations.

  2025cites this paper
• Inorganic Nanoparticles-based Drug Delivery Systems for Neurodegenerative Diseases Therapy.

  2025cites this paper
• "Unveiling Alzheimer's Disease (1901-2025): Historical Insights, Global Burden, Biological Mechanisms, Diagnostics, And Therapeutic Strategies".

  2025cites this paper
• Optimization of intranasal trifluoperazine/SPION-leciplex thermosensitive organogel for depression therapy: Pharmacodynamic and pharmacokinetic comparison of magnet placement effects on brain versus nose.

  2025cites this paper
• Nanoparticle-based strategies for overcoming the blood-brain barrier in CNS disorders and brain cancer: precision diagnostics and therapeutics for Alzheimer's, Parkinson's, multiple sclerosis, and glioblastoma.

  2025cites this paper
• Advanced intranasal peptide delivery systems for improved management of Alzheimer's disease.

  2025cites this paper
• Intranasal Therapeutics for Neurodegenerative Disorders: Overcoming the Blood-Brain Barrier with Smart Formulations and Devices.

  2025cites this paper
• Epigenetic Alterations in Alzheimer’s Disease: Impact on Insulin Signaling and Advanced Drug Delivery Systems

  2024cites this paper
• Peptide-based inhibitors and nanoparticles: Emerging therapeutics for Alzheimer's disease.

  2024cites this paper
• Recent progress in nanoparticulate-based intranasal delivery for treating of different central nervous system diseases

  2024cites this paper
• Liposomal Drug Delivery for Neurological Disorders: Advances and Challenges.

  2024cites this paper
• Liposomal Formulations of Anti-Alzheimer Drugs and siRNA for Nose-to-Brain Delivery: Design, Safety and Efficacy In Vitro

  2024cites this paper
• Advanced Noninvasive Strategies for the Brain Delivery of Therapeutic Proteins and Peptides.

  2024cites this paper
• Nanomaterials that Aid in the Diagnosis and Treatment of Alzheimer's Disease, Resolving Blood–Brain Barrier Crossing Ability

  2024cites this paper
• PEPTIDE DELIVERY VIA NASAL ROUTE: EXPLORING RECENT DEVELOPMENTS AND APPROACHES

  2024cites this paper
• Development of Nanomedicines for the Treatment of Alzheimer's Disease: Raison d'être, Strategies, Challenges and Regulatory Aspects.

  2024cites this paper
• BBD assisted in-situ Nanoliposomes of esculin hydrate via intranasal delivery for the amelioration of Parkinson’s disease

  2024cites this paper
• Lipid nanoparticle mediated small interfering RNA delivery as a potential therapy for Alzheimer's disease

  2024cites this paper
• Unravelling the in vivo dynamics of liposomes: Insights into biodistribution and cellular membrane interactions.

  2024cites this paper
• Optimization, Characterization and In-Vitro Cellular Uptake of Donepezil-Loaded NanoCrystVesicles

  2024cites this paper
• Nanoparticle delivery for central nervous system diseases and its clinical application

  2024cites this paper
• Nasal Delivery to the Brain: Harnessing Nanoparticles for Effective Drug Transport

  2024cites this paper
• Exploring Potential of Nano-formulations in the Treatment of Alzheimer's Disease through Nasal Route.

  2024cites this paper
• Recent Advances in Intranasal Liposomes for Drug, Gene, and Vaccine Delivery

  2023influential citation
• Nose-to-Brain (N2B) Delivery: An Alternative Route for the Delivery of Biologics in the Management and Treatment of Central Nervous System Disorders

  2023cites this paper
• Intranasal Drug Delivery by Nanotechnology: Advances in and Challenges for Alzheimer’s Disease Management

  2023cites this paper
• Unraveling the role of miRNAs in the diagnosis, progression, and therapeutic intervention of Alzheimer's disease.

  2023cites this paper
• Calming the Nerves via the Immune Instructive Physiochemical Properties of Self‐Assembling Peptide Hydrogels

  2023cites this paper
• A Comprehensive Review of Advanced Nasal Delivery: Specially Insulin and Calcitonin.

  2023cites this paper
• Nanomaterials as drug delivery agents for overcoming the blood-brain barrier: A comprehensive review

  2023influential citation
• Absorption enhancer approach for protein delivery by various routes of administration: a rapid review

  2023cites this paper
• A comprehensive and updated review on the applications of vesicular drug delivery systems in treatment of brain disorders: A shelter against storms

  2023cites this paper
• Nose-to-brain drug delivery for the treatment of CNS disease: New development and strategies.

  2023cites this paper
• Novel drug delivery system: Efficacy in Alzheimer’s disease

  2023cites this paper
• Nanovesicular-Mediated Intranasal Drug Therapy for Neurodegenerative Disease

  2023cites this paper
• The battle of lipid-based nanocarriers against blood-brain barrier: a critical review

  2023cites this paper
• 鼻腔药物递送的影响因素和提高递送效率的设计策略

  2023influential citation
• Novel liposomal formulations for protection and delivery of levodopa: structure-properties correlation.

  2023cites this paper
• Recent advances in nanotechnology for Intra-nasal drug delivery and clinical applications

  2023cites this paper
• Cell-Penetrating Peptides as Valuable Tools for Nose-to-Brain Delivery of Biological Drugs

  2023cites this paper
• Nanomedicine in the Management of Alzheimer’s Disease: State-of-the-Art

  2023cites this paper
• Recent Advancements in Nanomaterials: A Promising Way to Manage Neurodegenerative Disorders

  2023cites this paper
• Visualization and Characterization of Liposomes by Atomic Force Microscopy.

  2023cites this paper
• Brain-neuron targeted nanoparticles for peptide synergy therapy at dual-target of Alzheimer's disease.

  2023cites this paper
• Nose-to-brain drug delivery for the treatment of Alzheimer’s disease: current advancements and challenges

  2022cites this paper
• Recent nanoscale carriers for therapy of Alzheimer's disease: current strategies and perspectives.

  2022cites this paper
• Nanotechnology for the diagnosis and treatment of Alzheimer's disease: A bibliometric analysis

  2022cites this paper
• Dual-targeted magnetic mesoporous silica nanoparticles reduce brain amyloid-β burden via depolymerization and intestinal metabolism

  2022cites this paper
• A comprehensive review on carrier mediated nose to brain targeting: emphasis on molecular targets, current trends, future prospects, and challenges

  2022cites this paper
• Potential Drug Delivery Pathways for Treatment of Alzheimer’s Disease

  2022cites this paper
• Targeting Fibronectin to Overcome Remyelination Failure in Multiple Sclerosis: The Need for Brain- and Lesion-Targeted Drug Delivery

  2022cites this paper
• Insights for Alzheimer's disease pharmacotherapy and current clinical trials.

  2022cites this paper
• Blood–brain barrier: emerging trends on transport models and new-age strategies for therapeutics intervention against neurological disorders

  2022cites this paper
• Dendrimers in the context of targeting central nervous system disorders

  2022cites this paper
• Multifunctional icariin and tanshinone IIA co-delivery liposomes with potential application for Alzheimer’s disease

  2022cites this paper
• Exploring the impact of physicochemical properties of liposomal formulations on their in vivo fate.

  2022cites this paper
• Recent Trend of Nano-Particulate Carriers for the Diagnosis and Treatment of Alzheimer's disease.

  2022cites this paper
• Nano-immunotherapeutic strategies for targeted RNA delivery: Emphasizing the role of monocyte/macrophages as nanovehicles to treat glioblastoma multiforme

  2022cites this paper
• Nanoparticle delivery systems for substance use disorder

  2022cites this paper
• Cell models for Down syndrome-Alzheimer’s disease research

  2022cites this paper
• Review of Current Strategies for Delivering Alzheimer's Disease Drugs Across the Blood-Brain Barrier.

  2022cites this paper
• Modulation of olfactory area for effective transportation of actives in CNS disorders

  2022cites this paper
• Nose-to-brain/spinal cord delivery kinetics of liposomes with different surface properties.

  2022cites this paper
• Nano-lipidic formulation and therapeutic strategies for Alzheimer’s disease via intranasal route

  2021cites this paper
• Functional nanoassemblies for the diagnosis and therapy of Alzheimer's diseases.

  2021cites this paper
• Overcoming barriers by local drug delivery with liposomes.

  2021cites this paper
• Quality-by-Design-Based Development of n-Propyl-Gallate-Loaded Hyaluronic-Acid-Coated Liposomes for Intranasal Administration

  2021cites this paper
• Therapeutic Strategies and Nano-Drug Delivery Applications in Management of Aging Alzheimer's Disease.

  2021cites this paper
• Nanocarriers for Alzheimer’s disease: Research and patent update

  2021cites this paper
• Dynamic nanoassemblies for imaging and therapy of neurological disorders.

  2021cites this paper
• Mitochondrial nanomedicine: Subcellular organelle-specific delivery of molecular medicines.

  2021cites this paper
• Development of Imatinib Mesylate-Loaded Liposomes for Nose to Brain Delivery: In Vitro and In Vivo Evaluation

  2021cites this paper
• Recent progress in nanocarriers for direct nose to brain drug delivery

  2021cites this paper
• Intranasal Administration for Pain: Oxytocin and Other Polypeptides

  2021cites this paper
• Progress in nasal drug delivery systems.

  2021cites this paper
• Deconstructing Alzheimer’s Disease: How to Bridge the Gap between Experimental Models and the Human Pathology?

  2021cites this paper
• AN OVERVIEW ON CARRIER MEDIATED NOSE TO BRAIN DRUG DELIVERY SYSTEM

  2021cites this paper
• Nose-to-brain delivery of biologics and stem cells

  2021cites this paper
• Vesicular carriers for direct nose-to-brain drug delivery

  2021cites this paper
• Nanotechnological advances in direct nose-to-brain drug delivery for neurodegenerative disorders and other neuroailments

  2021cites this paper
• Intranasal route: The green corridor for Alzheimer's disease therapeutics

  2021cites this paper
• Intranasal delivery of phenytoin-loaded nanoparticles to the brain suppresses pentylenetetrazol-induced generalized tonic clonic seizures in an epilepsy mouse model.

  2021cites this paper
• Nanoparticle-Guided Brain Drug Delivery: Expanding the Therapeutic Approach to Neurodegenerative Diseases

  2021cites this paper
• Liposome based drug delivery as a potential treatment option for Alzheimer's disease

  2021cites this paper
• Lipid-Based Nanocarriers via Nose-to-Brain Pathway for Central Nervous System Disorders

  2021cites this paper
• Nanotherapeutics for Nose-to-Brain Drug Delivery: An Approach to Bypass the Blood Brain Barrier

  2021cites this paper
• Convolutions in the rendition of nose to brain therapeutics from bench to bedside: Feats & fallacies.

  2021cites this paper
• Drug Delivery Systems and Strategies to Overcome the Barriers of Brain.

  2021cites this paper
• Direct nose to the brain nanomedicine delivery presents a formidable challenge.

  2021cites this paper
• Liposomes: Production Methods and Application in Alzheimer's Disease.

  2021cites this paper
• Nanoparticlized System: Promising Approach for the Management of Alzheimer's Disease through Intranasal Delivery.

  2020cites this paper